![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Roche, AbbVie Snag Priority Review for Venetoclax
Roche, AbbVie Snag Priority Review for Venetoclax
![roche.gif](https://www.fdanews.com/ext/resources/test/Device_Images/roche.gif?t=1600727553&width=430)
January 19, 2016
Roche’s Genentech unit has scooped up priority review from the FDA for venetoclax for the treatment of chronic lymphocytic leukemia.
Developed in partnership with AbbVie, venetoclax is a small molecule inhibitor of the BCL-2 protein. It received breakthrough therapy designation in April 2015.
Upcoming Events
-
21Oct